読み込み中
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children’s Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
前日終値
$8.93
+$0.11 · +1.25%
日中の時刻はETです。市場データは遅延する場合があります。
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children’s Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
日中レンジ
現在 $8.93
52週レンジ
現在 $8.93
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
36
割高
センチメント
67
強気
リスク
65
高リスク
モメンタム
69
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children’s Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
日中レンジ
現在 $8.93
52週レンジ
現在 $8.93
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（AUD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 4.2万 AUD | 230.8万 AUD | 555 AUD | 1万 AUD | 1518.3万 AUD |
| 粗利益 | 4.2万 AUD | 230.8万 AUD | 555 AUD | 1万 AUD | 1518.3万 AUD |
| 研究開発 | 732.6万 AUD | 1738万 AUD | 1556.41万 AUD | 2016.9万 AUD | 1454.1万 AUD |
| 販売・一般管理 | 872万 AUD | 1356.3万 AUD | 858.3万 AUD | 524万 AUD | 702万 AUD |
| 営業費用 | 1425.9万 AUD | 3077万 AUD | 2412.45万 AUD | 2540.9万 AUD | 2155.9万 AUD |
| 受取利息 | 7.2万 AUD | 1.2万 AUD | 2.28万 AUD | 2094 AUD | 4.22万 AUD |
| 支払利息 | — | — | — | 2094 AUD | — |
| 減価償却費と償却費 | 93.4万 AUD | 186.9万 AUD | 186.9万 AUD | 186.9万 AUD | 126.5万 AUD |
| 営業利益 | −1421.7万 AUD | −2846.2万 AUD | −2412.4万 AUD | −2539.9万 AUD | −637.6万 AUD |
| 純利益 | −2070.2万 AUD | −2677.8万 AUD | −2046.52万 AUD | −2501.4万 AUD | −842万 AUD |
会社概要が更新されました 2026年10月12日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
評価サンプルは3件と限定的です
| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2025年4月17日 | 1:5 | — | — |
株式分割 | 2024年10月28日 | 1:10 | — | — |
株式分割 | 2020年10月2日 | 1,041:1,000 | — | — |
株式分割 | 2017年7月14日 | 1:4 | — | — |
株式分割 | 2013年1月28日 | 1,519:500 | — | — |
株式分割 | 2012年1月3日 | 1:5 | — | — |
発効済み 2025年4月17日
1:5
発効済み 2024年10月28日
1:10
発効済み 2020年10月2日
1,041:1,000
発効済み 2017年7月14日
1:4
発効済み 2013年1月28日
1,519:500
発効済み 2012年1月3日
1:5
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
